Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MDIIHIVIA

Financiado

Cerrado

Mechanisms of deaminase independent inhibition of HIV infection by APOBEC3 prote...

Mechanisms of deaminase independent inhibition of HIV infection by APOBEC3 proteins "The human immunodeficiency virus (HIV) continues to be a major public health issue. Current treatments can slow down disease progression, but high costs, severe side effects and the emergence of drug-resistant strains all call fo... ver más

30/04/2015

KINGS COLLEGE LOND...

231K€

Presupuesto del proyecto: 231K€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-04-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

THINPAD Targeting the HIV 1 Nucleocapsid Protein to fight Antiretrov... 7M€ Cerrado

SAF2008-01729 REGULACION DE LA INFECCION POR VIH-1 MEDIADA POR HDAC6 EN LA... 121K€ Cerrado

VIRALMORPHMECH Towards a complete spatiotemporal model of viral morphogenes... 100K€ Cerrado

NEF-PATHOGENESIS The importance of Nef effects on HIV 1 infectivity for viral... 260K€ Cerrado

BIO2013-48788-C2-1-R FIDELIDAD DE POLIMERASAS VIRALES QUE COPIAN MOLDES ARN Y SU... 133K€ Cerrado

JCI-2010-07428 The quasispecies dynamics and lethal mutagenesis of RNA viru... 101K€ Cerrado

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 231K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "The human immunodeficiency virus (HIV) continues to be a major public health issue. Current treatments can slow down disease progression, but high costs, severe side effects and the emergence of drug-resistant strains all call for the development of new treatment regimes. The detailed understanding of virus-host interactions is of utmost importance for this endeavor. The cytidine deaminase APOBEC3 (A3) proteins, and in particular APOBEC3G (A3G), are potent host restriction factors that can be packaged into assembling HIV-1 virions and severely compromise viral infectivity. To evade this powerful restriction, HIV-1 relies on the vif (viral infectivity factor) protein, which has evolved to promote proteasome-dependent A3G degradation. Despite intensive research and the high potential of the vif-A3G axis for therapeutic intervention, the precise mechanisms of A3G packaging and HIV inhibition are not fully understood. As a polynucleotide editing enzyme, A3G induces hypermutation in the viral genomic DNA. Additionally, it has recently become evident that A3G also interferes with the process of reverse transcription in a deaminase-independent way. The research proposed here is designed to elucidate the molecular basis of A3G-mediated inhibition of cDNA synthesis during reverse transcription using a combination of experimental approaches and systems. This involves: 1) The assessment of reverse transcription efficiency in the presence and absence of A3 proteins in vitro as well as in physiologically relevant human CD4+ T cells. Importantly, this will include a novel assay designed to map 3’ termini of nascent viral cDNA products. 2) Mapping of A3G binding sites on viral genomic RNA and identification cellular RNA binding partners using CLIP (crosslinking and immunoprecipitation) assays. 3) A detailed investigation of A3G’s interaction with components of the reverse transcription complex (RTC)."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores